Novartis Investigative Site

Corbeil-Essonnes 91100

0 studies enrolling now · 8 studies all time

What they study most

Acute Myocardial Infarction, Atherosclerotic Cardiovascular Disease, Breast Cancer, Cardiovascular Disease, Cardiovascular Disease and Lipoprotein(a), Chronic Myelogenous Leukemia, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction (HF-rEF), Type 2 Diabetes Mellitus

Studies at this site

• Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease — Running, not enrolling
• Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients — Completed
• Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC — Completed
• Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI — Completed
• Lipoprotein(a) in Patients With Cardiovascular Disease (CVD) — Completed
• A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients — Completed
• Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF) — NO_LONGER_AVAILABLE
• Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases) — Stopped early